A detailed history of Pluribus Labs, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Pluribus Labs, LLC holds 953 shares of REGN stock, worth $705,229. This represents 1.03% of its overall portfolio holdings.

Number of Shares
953
Previous 470 102.77%
Holding current value
$705,229
Previous $328,000 71.65%
% of portfolio
1.03%
Previous 1.3%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$548.35 - $738.84 $264,853 - $356,859
483 Added 102.77%
953 $563,000
Q1 2022

May 16, 2022

BUY
$595.12 - $698.43 $279,706 - $328,262
470 New
470 $328,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $79.3B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Pluribus Labs, LLC Portfolio

Follow Pluribus Labs, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pluribus Labs, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pluribus Labs, LLC with notifications on news.